Merck & Co., Inc.’s (MRK) Buy Rating Reiterated at Truist Financial

Truist Financial reissued their buy rating on shares of Merck & Co., Inc. (NYSE:MRKFree Report) in a report released on Thursday morning, Benzinga reports. Truist Financial currently has a $142.00 target price on the stock, up from their previous target price of $139.00.

Other equities analysts have also issued research reports about the stock. Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the company an equal weight rating in a report on Wednesday, March 27th. UBS Group increased their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a buy rating in a report on Friday, February 2nd. Cantor Fitzgerald reaffirmed an overweight rating and set a $135.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, March 27th. StockNews.com raised shares of Merck & Co., Inc. from a buy rating to a strong-buy rating in a report on Friday, February 2nd. Finally, Societe Generale lowered shares of Merck & Co., Inc. from a hold rating to a sell rating and set a $104.00 target price on the stock. in a report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $129.71.

Check Out Our Latest Research Report on MRK

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $131.95 on Thursday. The firm’s fifty day moving average price is $125.01 and its 200-day moving average price is $112.85. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. The stock has a market cap of $334.18 billion, a P/E ratio of 942.50, a price-to-earnings-growth ratio of 0.52 and a beta of 0.37. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. The firm had revenue of $14.63 billion for the quarter, compared to analysts’ expectations of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company posted $1.62 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 8.59 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 2.33%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is currently 2,200.00%.

Insider Activity at Merck & Co., Inc.

In related news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares in the company, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Several hedge funds have recently bought and sold shares of the business. NTV Asset Management LLC boosted its stake in Merck & Co., Inc. by 0.3% during the fourth quarter. NTV Asset Management LLC now owns 26,534 shares of the company’s stock worth $2,893,000 after acquiring an additional 80 shares in the last quarter. SRS Capital Advisors Inc. boosted its stake in Merck & Co., Inc. by 1.6% during the fourth quarter. SRS Capital Advisors Inc. now owns 5,037 shares of the company’s stock worth $549,000 after acquiring an additional 81 shares in the last quarter. Endowment Wealth Management Inc. boosted its stake in Merck & Co., Inc. by 3.2% during the fourth quarter. Endowment Wealth Management Inc. now owns 2,637 shares of the company’s stock worth $288,000 after acquiring an additional 81 shares in the last quarter. Empire Financial Management Company LLC boosted its stake in Merck & Co., Inc. by 0.3% during the fourth quarter. Empire Financial Management Company LLC now owns 26,055 shares of the company’s stock worth $2,841,000 after acquiring an additional 82 shares in the last quarter. Finally, Ironwood Wealth Management LLC. lifted its stake in shares of Merck & Co., Inc. by 1.5% in the fourth quarter. Ironwood Wealth Management LLC. now owns 5,612 shares of the company’s stock worth $612,000 after buying an additional 83 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.